Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1995 Aug;121(8):469–473. doi: 10.1007/BF01218363

Doxorubicin-heparin complex: reduction of cardiotoxicity of doxorubicin

Yumi Mizuno 1,✉, Toshiro Hara 1,2, Shigeyuki Tachibana 3, Kohki Uragoh 1,4, Kouhei Akazawa 5, Kohji Ueda 1
PMCID: PMC12201602  PMID: 7642689

Abstract

We have compared the antitumor activity and cardiotoxicity of free doxorubicin (Dox) and doxorubicinheparin complex in vivo and in vitro. Dox and Dox-heparin complex equally inhibited the DNA synthesis of leukemic cells and showed a similar anticancer activity against tumor-bearing mice. Acute toxicity of Dox at the dose of 20 mg/kg or 30 mg/kg was significantly more profound than that of the Dox-heparin complex, which was demonstrated by survival rate (P<0.01). Chronic toxicities of Dox and the Dox-heparin complex were compared by giving the respective reagent (2 mg/kg) weekly for 20 weeks. The weight gains of the mice given Dox-heparin complex were greater than those of the mice given Dox alone (P<0.01). The pathological damage to the cardiac tissue in mice treated with Dox-heparin complex was significantly less severe than that of mice treated with Dox. Thus, the present study indicates that complexing with heparin diminished the acute and chronic toxicity of Dox without reducing its antitumor activity in mice, and suggests a possible clinical application of Dox-heparin complex in humans.

Key words: Doxorubicin, Doxorubicin-heparin complex, Cardiotoxicity, Antitumor activity

Abbreviation

Dox

doxorubicin

References

  1. Aoyama T, Horioka M, Nagamitus S (1987) Macromolecular complex of drugs I. Doxorubicin-heparin complex. Chem Pharm Bull (Tokyo) 35: 808–813 [DOI] [PubMed] [Google Scholar]
  2. Atassi G, Tagnon J (1974) Comparison of Adriamycin with the DNA-Adriamycin complex in chemotherapy of L1210 leukemia. Eur J Cancer 10: 399–403 [DOI] [PubMed] [Google Scholar]
  3. Basser RB, Green MD (1993) Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev 19: 57–77 [DOI] [PubMed] [Google Scholar]
  4. Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62: 865–872 [PubMed] [Google Scholar]
  5. Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88: 168–175 [DOI] [PubMed] [Google Scholar]
  6. Campeneere DD, Jarnke R, Trouet A, Baudon H, Maldague P (1980) DNA-anthracycline complexes. II. Comparative study of the acute lesions induced in mice after intravenous administration of free and DNA-bound Adriamycin. Eur J Cancer 16: 987–998 [DOI] [PubMed] [Google Scholar]
  7. Cofrancesco E, Vigo A, Pogliani E (1980) Antiheparin activity of Adriamycin. Thromb Res 18: 743–746 [DOI] [PubMed] [Google Scholar]
  8. Colombo T, Delaini F, Ferrari R, Donati MB, Donelli G, Poggi A (1981) Interaction between heparin and Adriamycin in mice bearing the Lewis lung carcinoma. Biomedicine 34: 124–128 [PubMed] [Google Scholar]
  9. Foa P, Cofrancesco E, Lombardi L, Colombi M, Pogliani EM, Polli EE (1983) Non interference by heparin with the cytostatic effect of Adriamycin: an in vitro study on a human promyelocytic leukemia cell line. Br J Cancer 48: 735–738 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gabizon A, Meshorer A, Barenhoiz Y (1986) Comparative longterm study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 77: 459–468 [PubMed] [Google Scholar]
  11. Green MD, Alderton P, Sobol MM, Gross J, Muggia FM, Speyer JL (1992) ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies. In: Muggia FM (ed) New drugs, concepts and results in cancer chemotherapy. Kluwer, Boston, pp 101–117 [DOI] [PubMed] [Google Scholar]
  12. Hoesel QGCM, Steerenberg PA, Crommelin DJA, Dijk A, Oort W, Klein S, Douze JMC, Wildt DJ, Hillen FC (1984) Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl Rat. Cancer Res 44: 3698–3705 [PubMed] [Google Scholar]
  13. Hoff DD, Rozencweig M, Piccart M (1982) The cardiotoxicity of anticancer agents. Semin Oncol 9: 23–32 [PubMed] [Google Scholar]
  14. Hybrechts M, Symann M, Trouet A (1979) Effects of daunorubicin and doxorubicin, free and associated with DNA, on hemopoietic stem cells. Cancer Res 39: 3738–3743 [PubMed] [Google Scholar]
  15. Kruscal WH, Wallis WA (1952) Use of ranks in one-criterion variance analysis. J Am Statist Assoc 49: 583–621 [Google Scholar]
  16. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324: 808–815 [DOI] [PubMed] [Google Scholar]
  17. Mezonni M, Arcamona F (1978) Binding of Adriamycin to sulphated mucopolysaccharides. Biochem Biophys Res Commun 80: 313–318 [DOI] [PubMed] [Google Scholar]
  18. Olson RD, Mudhlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4: 3076–3086 [PubMed] [Google Scholar]
  19. Paul C, Lonnqvist B, Gahrton G, Lockner D, Peterson C (1981) Reducing the cardiotoxicity of anthracyclines by complex-binding to DNA: report of three cases. Cancer 48: 1531–1534 [DOI] [PubMed] [Google Scholar]
  20. Pihkala J, Sariola H, Saarinen UM (1994) Myocardial function and postmortem myocardial histology in children given anthracycline therapy for cancer. Pediatr Hematol Oncol 11: 259–269 [DOI] [PubMed] [Google Scholar]
  21. Rahman A, White G, More N, Scheih PS (1985) Pharmacological, toxicological and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. Cancer Res 45: 795–803 [PubMed] [Google Scholar]
  22. Rinehart JJ, Lewis RP, Balcerzak SP (1974) Adriamycin cardiotoxicity in man. Ann Intern Med 81: 475–478 [DOI] [PubMed] [Google Scholar]
  23. Saltiel E, McGuire W (1983) Doxorubicin (Adriamycin) cardiomyopathy. A critical review. West J Med 139: 332–341 [PMC free article] [PubMed] [Google Scholar]
  24. Shapira J, Gotfried M, Lishner M, Ravid M (1990) Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 65: 870–873 [DOI] [PubMed] [Google Scholar]
  25. Taylor AL, Applefeld MM, Wiernik PH, Grochow LB, Mader LC, Bulkey BH (1984) Acute anthracycline cardiotoxicity. Comparative morphologic study of three analogues. Cancer 53: 1660–1666 [DOI] [PubMed] [Google Scholar]
  26. Trouet A, Campeneere DD, Malengreaux MS, Atassi G (1974) Experimental leukemia chemotherapy with a “liposomotropic” Adriamycin-DNA complex. Eur J Cancer 10: 405–411 [DOI] [PubMed] [Google Scholar]
  27. Umezawa H, Takahashi Y, Kinoshita M (1979) Tetrahydropyranyl derivatives of daunomycin and Adriamycin. J Antibiot 32: 1082–1084 [DOI] [PubMed] [Google Scholar]
  28. Unverferth DV, Magorien RD, Leier CV, Balcerzak SP (1982) Doxorubicin cardiotoxicity. Cancer Treat Rev 9: 149–164 [DOI] [PubMed] [Google Scholar]
  29. Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B (1986) Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol 18: 185–197 [DOI] [PubMed] [Google Scholar]
  30. Yeung ST, Yoong C, Spink J, Galbraith A, Smith PJ (1991) Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 337: 816–818 [DOI] [PubMed] [Google Scholar]
  31. Yeung TK, Jaenke RS, Wilding D, Creighton AM, Hopewell JW (1992) The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother Pharmacol 30: 58–64 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES